Mentioned in the company presentation, 22 November
Slide 8
New products and new category opportunities via alliances:
- breast reconstruction
- soft tissue reinforcement
- orthobiologics (bone, tendon, ligament repair)
- delivery of therapeutics (anti-microbials, drug elution, cell-based therapies)
Slide 9
- Alliances with global category leaders and academia for Clinical & Health-economics evidence
- Opportunity to enter breast reconstruction, soft tissue reinforcement, orthobiologics, delivery of therapeutics
Slide 12
Syntrel –
- Targeting the US$2.5bn hernia and abdominal wall reconstruction market via the Syntrel family of products, and currently evaluating several design options with key opinion leaders
- Developing modified NovoSorb products for soft tissue reinforcement
- Breast reconstruction development in-house
- Exploring alliances for Orthobiologics (bone, tendon, ligament regeneration)
- Investigating NovoSorb-based products for Type I diabetes and supplying NovoSorb to Beta-Cell Technologies (3rd party) for clinical trials
- Co-Development of Composite Cultured Skin for single-stage skin replacement
- NovoSorb Drug Elution Depot (pellet), involving the integration of drug treatment into the NovoSorb polymer
- Incorporation of anti-microbials into NovoSorb polymer for controlled release for infection management
It’s a bit unclear, but there definitely seems to be an intention to form alliances for development of orthobiologics (bone, tendon, ligament repair) and therapeutics delivery (anti-microbials, drug elution, cell-based therapies).
Non-academia alliances are expected to be with “global category leaders”.
- Forums
- ASX - By Stock
- PNV
- Ann: Webcast Recording - Investor Presentation and Update
Ann: Webcast Recording - Investor Presentation and Update, page-6
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
|
|||||
Last
$2.33 |
Change
-0.020(0.85%) |
Mkt cap ! $1.608B |
Open | High | Low | Value | Volume |
$2.32 | $2.34 | $2.29 | $1.770M | 763.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5901 | $2.33 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.34 | 6302 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3361 | 2.330 |
5 | 11320 | 2.320 |
2 | 8436 | 2.310 |
7 | 44931 | 2.300 |
7 | 8112 | 2.290 |
Price($) | Vol. | No. |
---|---|---|
2.350 | 36820 | 7 |
2.360 | 8436 | 2 |
2.370 | 4427 | 2 |
2.380 | 2207 | 1 |
2.390 | 2207 | 1 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online